ArticleThe American journal of case reports2025
Andexanet Alfa in Urgent Cardiac Surgery: A Case Report of Edoxaban Reversal for Acute Hemopericardium.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotics and Other Drugs Removal by the CytoSorbAntibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Antidotes to non-vitamin K oral anticoagulants (NOAK) like idarucizumab and andexanet alfa have been approved for reversing the effects of dabigatran and apixaban/rivaroxaban, respectively. However, andexanet alfa is not approved for reversing edoxaban. Current guidelines recommend using specific reversal agents in emergencies, but they do not support andexanet alfa for edoxaban reversal. This study illustrates the off-label use of andexanet alfa for edoxaban reversal in a case of acute hemopericardium requiring urgent cardiac surgery, addressing the practical challenges and clinical outcomes. CASE REPORT We report the case of a 71-year-old woman who required urgent cardiac surgery following acute pericardial tamponade caused by hemopericardium during right-heart catheterization. After emergency pericardiocentesis, andexanet alfa was administered to address any residual effects of edoxaban (Lixiana), along with protamine to reverse the effects of heparin. The patient was transferred in stable condition for cardiac surgery, where a right ventricular perforation responsible for the hemopericardium was sutured, and mitral valve replacement was performed via cardiopulmonary bypass (CPB) due to severe mitral valve regurgitation. No adverse cerebrovascular, hemorrhagic, or thromboembolic events were observed. CONCLUSIONS This case demonstrates an unconventional off-label use of andexanet alfa to stabilize a patient on edoxaban. Although the patient did not have any adverse effects, the thromboembolic risks of andexanet alfa and potential heparin resistance warrant cautious use, especially before cardiac surgery. Successful management was achieved through a multidisciplinary approach. Further research is needed to evaluate the safety and efficacy of andexanet alfa in patients on edoxaban therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.